CRISPR Therapeutics Director Simeon George Reports Disposal of Common Shares Worth $720,373.362
CRISPR Therapeutics director Simeon George sold 14,514 Common Shares on October 14, 2026, at $49.633 per share. He also exercised stock options for 30,000 Common Shares at $14 per share that day. Following the transactions, George directly owned 15,486 Common Shares and indirectly held 2,038,763 Common Shares. Disclaim